To investigate whether ethanol ablation by using a multipronged needle delivery system (multipronged ethanol ablation) could eradicate hepatocellular carcinoma (HCC) up to 5.0 cm in diameter with a single-session high-dose strategy.
H epatocellular carcinoma (HCC) is one of the most common cancers worldwide, and its incidence is increasing (1, 2) . Patients at an early stage of HCC (one HCC of Յ 5.0 cm in diameter or three nodules of Յ3.0 cm in diameter each) benefit from curative therapies, such as hepatic resection, liver transplantation, or percutaneous ablation (3) (4) (5) . Percutaneous local ablative therapies are the best option for such patients who are not candidates for resection or transplantation (6) (7) (8) . Besides, about half of patients develop tumor recurrence within 2 years after resection, and the incidence rises to 70%-85% within 5 years (9) (10) (11) . Although repeated hepatectomy is the most effective treatment for recurrent HCC, impaired liver function and/or the presence of multicentric tumors limits its use in more than 80% of recurrent cases (12) . Percutaneous ablation is particularly suitable for treating recurrent HCC because postsurgical recurrence can be detected at an early stage while the nodules are still small and, therefore, amenable to percutaneous ablation (13) .
During the past 20 years, ethanol ablation (also named percutaneous ethanol injection) has been widely used as a secondary option when surgery is precluded in patients with early HCC (5, 14) . However, routine ethanol ablation accomplishes limited necrosis in tumors larger than 3 cm, because of the incomplete ethanol infiltration inside the whole tumor tissue that results from the incapability of disrupting the intratumoral septa and/or inadequate placement of the needle (3, 5) . Moreover, ethanol ablation often requires repeated injections on separate days for completion of a treatment (15) . Researchers in randomized clinical trials (16) (17) (18) revealed that a higher rate of complete response with fewer treatment sessions, compared with ethanol ablation, can be achieved with thermal ablative techniques, such as radiofrequency (RF) ablation. However, RF ablation of tumors at a subcapsular location or adjacent to a critical structure, such as the hepatic hilum or gallbladder, increases the complication rate (19, 20) above the reported baseline of 7%-10% (19, 21) . In an intention-to-treat analysis, Lencioni et al (22) reported that 9% of tumors could not be treated by using RF ablation because of the high-risk location of the tumor. On the contrary, ethanol ablation is a low-risk procedure with a major complication rate of 1.3%-3.2% and a mortality rate of 0.09%, as indicated in a clinical study in which 270 patients with HCC were enrolled (23) . Therefore, percutaneous ethanol injection will continue to play a role in the treatment of HCC (14) .
To improve the conventional ethanol ablation technique, a retractable multipronged injection needle was developed (24) . The purpose of this study was to investigate whether ethanol ablation by using this needle delivery system (multipronged ethanol ablation) could eradicate HCC up to 5.0 cm in diameter with a single-session high-dose strategy, and we evaluated the treatment responses and complications.
Materials and Methods
This study was performed according to the guidelines of the Helsinki Declaration, and the study was approved by the ethics committee of the First Affiliated Hospital of Sun Yat-Sen University (Guangzhou, People's Republic of China). Written informed consent was obtained from each patient before treatment. 
Patients
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Advances in Knowledge
Ⅲ Ethanol ablation with a multipronged needle (multipronged ethanol ablation) enabled the intratumoral delivery of high-dose ethanol in multiple directions with one injection. Ⅲ High doses of ethanol used in one treatment session for ablation of hepatocellular carcinoma (HCC) up to 5.0 cm in diameter could be safely injected, with local anesthesia and low frequency of severe complications. Ⅲ HCC up to 5.0 cm in diameter could be completely eradicated by using multipronged ethanol ablation with one to two treatment sessions. Ⅲ Multipronged ethanol ablation could destroy tumors at unfavorable locations effectively and safely. /L) or more or prothrombin activity of more than 50%; (f) tumors with a location considered unfavorable for ablation by using other techniques, defined as tumors located close (Ͻ5 mm) to the tumor capsule, the gallbladder, the gastrointestinal tract, the inferior vena cava, the hilum, the heart, or the diaphragm; and (g) a tumor that was not suitable for resection or the patient declined surgery or RF ablation. Patients with liver function test results with Child-Pugh class C disease, those with uncontrolled coagulopathy, or those with a history of ethanol allergy were excluded from the study. Cirrhosis of the liver was determined by means of a combined assessment of hepatitis history, clinical manifestations, and imaging findings. Portal hypertension was defined as the existence of esophageal varices or splenomegaly, with a platelet count of less than 100 ϫ 10 3 /L (100 ϫ 10 9 /L). Diagnosis of HCC was confirmed with USguided fine-needle biopsy in 102 patients or with noninvasive means (8) in 39 patients. Tumor diameters were determined as the largest dimension measured by using US. The numbers of the tumors were determined with US and contrast material-enhanced computed tomographic (CT) findings. B-mode US was used to detect vascular invasion. Tumor capsule was defined as the presence of a peritumoral hypoechoic halo on a US image. Diagnostic and treatment decisions were made in consensus by a team of hepatobiliary surgeons and interventional radiologists.
Multipronged Ethanol Ablation Equipment
A multipronged injection needle device (Quadra-Fuse; Rex Medical, Raleigh, NC) was used for ethanol ablation. This device includes an 18-gauge 20-cm-long puncture needle consisting of an echogenic tip; three retractable tines, each with two evenly spaced through-holes (four fluid exits); and a connector with extension tubing (Fig 1) . The extent of tine deployment could be adjusted up to 5 cm.
Imaging Equipment
A real-time US scanner (Acuson Sequoia 512; Siemens, Berlin, Germany), with a 2-5-MHz vector transducer and a puncture guide device, was used in this study. During contrast-enhanced US, the mechanical index value ranged from 0.15 to 0.21 for contrast pulse sequencing. The contrast agent (SonoVue; Bracco, Milan, Italy) was administered intravenously at a dose of 2.4 mL per injection in a bolus fashion (within 1-2 seconds), followed by a flush of 5 mL of normal saline. The target tumor was observed continuously for 6 minutes, including arterial (8 -30 seconds from the beginning of contrast agent injection), portal (31-120 seconds), and late (121-360 seconds) phases. B-mode US was performed for all procedures as stated previously and at follow-up. Contrast-enhanced US was used for identification of intrahepatic tumors. US was performed by two of three authors (including X.Y.X., H.X.X., and G.J.L., who had 20, 13, and 7 years of experience, respectively, with US).
Contrast-enhanced CT was performed by using a single-section helical CT scanner (Xpress/SX; Toshiba, Tokyo, Japan) before October 2005 and a 64-section helical CT scanner (Aquilion; Toshiba) thereafter. The single-section helical CT parameters included 5-mm collimation, a pitch of 1.0, 120 kV, and 250 mAs. The 64-section CT protocol involved a 0.5 mm section thickness and 64 detector rows, 120 kV, and 150 -200 mAs. The standard dual-phase scan procedure was used. After an unenhanced helical scan was obtained through the liver, 50 -100 mL (1.5 mL/kg) of nonionic iodinated contrast material (Ultravist; Schering, Berlin, Germany) was administered through the antecubital vein by using a power injector (Stellant D; Medrad, Indianola, Pa) at a rate of 3 mL/sec (single-section CT) or 4 mL/sec (64-section CT). The arterial phase sequence was performed 25-32 seconds after injection, and a portal venous phase sequence was performed at 50 -60 seconds. Contrastenhanced CT was used for diagnosis in cases in which patients did not undergo biopsy and for follow-up after ablation in all cases.
Treatment Procedure
Patients were hospitalized before the treatment. Local anesthesia was achieved with 1% lidocaine hydrochloride (Hui Da Pharmaceutical, Shan Xi, People's Republic of China), and conscious analgesia-sedation was induced by means of intravenous administration of 0.1 mg of tramadol hydrochloride (Grunenthal, Aachen, Germany), 2.5 mg of droperidol (Xu Dong Hai Pu Pharmaceutical, Shanghai, China), and 0.1 mg of fentanyl citrate (Yi Chang Pharmaceutical, Hu Bei, China). Ablation procedures were performed by two authors (M.K., X.Y.X., who had 10 and 13 years of experience with ablation, respectively). With US 
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Kuang et al guidance, the needle was introduced percutaneously into the center of the tumor nodule and the needle tip was positioned at the bottom of the target tumor. The maximal extent of tine deployment followed the intention of accomplishing an ablative margin of 0.5-1.0 cm or was equal to the largest diameter of the target tumor in cases where tumor was close to critical structures. An injection-rotationinjection (IRI) maneuver was used. To treat an HCC of 3.0 cm or smaller in diameter, the three tines were deployed initially at the pretreatment-decided maximum extent, and the first half of the planned volume of ethanol was injected. While injecting the ethanol, the tines were gradually withdrawn with a 1-cm deployment interval until they were completely retracted into the needle cannula. After completion of the first injection, the needle was rotated 60°, and the tines were redeployed to the former maximum extent. Injection of another half of the volume of ethanol with the same tinewithdrawing process was performed. Ablation of a tumor that was 3.1-5.0 cm in diameter required two rounds of IRI maneuvers (four injections overall, 25% of the planned ethanol volume per injection). After the injection of half of the planned ethanol volume at the far end of the tumor with the first round of the IRI maneuver, the tines were completely retracted and the needle was withdrawn 1-2 cm. The second round of the IRI maneuver, including deployment of tines, rotation of needle, and redeployment of the tines, was performed accompanied with the injection of the other half of the ethanol. If excessive leakage of ethanol into the large intrahepatic vessels was observed, injection was stopped immediately and the tines were redeployed in other directions. During any necessary pause of the ethanol injection, 0.5-1 mL of saline solution treated with heparin was immediately injected to prevent possible thrombosis in the tines. After the completion of all injections, the needle was left in the tumor for 1-2 minutes to prevent possible ethanol reflux and then was removed. The ethanol was injected until the whole tumor appeared completely hyperechoic (7). The volume of injected eth- 
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anol depended on the tumor size and patient compliance. For tumors of 3.0 cm or smaller in diameter, the volume of injected ethanol was calculated as the volume of an oversized sphere, as follows:
, where V is volume in milliliters and D is the largest tumor dimension in centimeters. For tumors that were 3.1-5.0 cm in diameter, the least amount of ethanol was equal to the volume of the tumor (V ϭ 4/3 [(D/2) 3 ]), and the upper limit of ethanol volume per session was 60 mL, to minimize toxic effects of ethanol to the patient (25) . The injection was stopped when the calculated volume was reached or if clinical symptoms, such as choking, coughing, or tachycardia (Ͼ120 beats per minute), occurred. For patients with two to three HCC nodules, multipronged ethanol ablation of all tumors was performed in one session, following the same strategies mentioned previously. In cases in which the total amount of injected ethanol was more than 60 mL, two sessions of treatment, 1 week apart, were performed.
Assessment of Treatment Response and Follow-up
Local effectiveness of multipronged ethanol ablation was assessed by using contrast-enhanced CT performed 1 month after the treatment, as immediate postablation CT is difficult to perform in our hospital. Primary technique effectiveness (PTE), local tumor progression (LTP), and intrahepatic distant recurrence (DR) in this study were assessed on a patientby-patient basis. Image interpretation was performed in consensus by two authors (H.X.X., G.J.L., who had 10 and 5 years of experience with abdominal CT interpretation, respectively). Treatment response was defined following the reporting criteria of image-guided tumor ablation (26) . Technical success meant that the tumor was treated according to the protocol. Complete ablation was defined as no enhancement in the tumor area assessed by using CT 1 month after treatment. Another session of multipronged ethanol ablation was performed if CT revealed a residual tumor. If the tumor was still viable after two treatment sessions, ethanol ablation was considered to have failed and the patient was referred for other therapies. PTE rate was the percentage of tumors in which complete ablation was achieved after one or two treatment sessions. Patients with tumors in which PTE was achieved entered follow-up. Follow-up was performed by using US and the serum ␣-fetoprotein (AFP) level every 3 months and contrastenhanced CT every 6 months.
LTP was defined as the regrowth of tumor inside the initially completely ablated nodule. DR was defined as the appearance of new intrahepatic tumors other than in the treated area. In cases with suspicious US findings and/or an elevated AFP level, contrast-enhanced US plus contrast-enhanced CT or fine-needle biopsy was performed. For patients with LTP or DR, additional treatment with ethanol ablation, RF ablation, microwave ablation, or transarterial chemoembolization was offered. Any ethanol ablation-related major complications, minor complications, and side effects were defined according to Goldberg et al (26) and were documented by two authors (X.Y.Y., Z.F.X.) with chart and image reviews.
Statistical Analysis
Software (SPSS package, version 13.0; SPSS, Chicago, Ill) was used for statistical analysis. Continuous data were expressed 
Results
Patients and Tumor Profile
One hundred twenty-four (88%) patients had underlying cirrhosis. One hundred thirty-one (93%) patients had Child-Pugh class A disease, and the remaining 10 (7%) had Child-Pugh class B disease. Forty-two (30%) patients had portal hypertension. The serum AFP level was 200 g/L or lower in 95 (67%) patients and elevated (Ͼ200 g/L) in 46 (33%) patients. Eighty-eight (62%) patients received a first-time diagnosis of HCC, and 53 (38%) had recurrence after hepatectomy (n ϭ 25), microwave ablation (n ϭ 12), RF ablation (n ϭ 13), and transarterial chemoembolization (n ϭ 3). The tumor nodules ranged in diameter from 1.3 to 5.0 cm (mean, 2.9 cm Ϯ 0.9 [standard deviation]). There were 81 (57%) patients with tumors of 3.0 cm or smaller in diameter and 60 (43%) patients with tumors of 3.1-5.0 cm in diameter. One hundred (71%) patients had capsulated tumors and 41 (29%) had noncapsulated HCC. Eighty-nine (63%) patients had nodules located at unfavorable sites. The detailed characteristics of the patients and tumor profiles are shown in Table 1 . The mean hospitalization time was 3 days Ϯ 3 (range, 1-23 days).
Local Effectiveness and Recurrence
Technical success was achieved in all patients; no treatment sessions were prematurely terminated due to immediate procedural complications. A total of 158 multipronged ethanol ablation sessions were performed (mean, 1.1 ses- Table 2 ). The complete ablation rate after the first multipronged ethanol ablation session was 88% (124 of 141) on a patientby-patient basis and 89% (146 of 164) on a tumor-by-tumor basis (Figs 2-4) . In 17 patients with a residual viable tumor, complete ablation was achieved with a second session of multipronged ethanol ablation in 10 patients. Overall, PTE was achieved in 95% (134 of 141) of patients. In patients with tumors of 3.0 cm or smaller in diameter and those with tumors of 3.1-5.0 cm in diameter, the PTE rate was 99% (80 of 81) and 90% (54 of 60), respectively ( Table 2) . Significantly better PTE rates were achieved in patients with capsulated tumors, those with small tumors (Յ3.0 cm in diameter), those without portal hypertension, and those with a normal platelet count than were achieved in patients with noncapsulated tumors, those with intermediate tumors (3.1-5.0 cm in diameter), those with portal hypertension, and those with a low platelet count (P ϭ .022, .042, .025, and .031, respectively). However, multivariate analysis revealed that only tumor pattern was an independent risk factor for PTE (Table 3) .
Figure 3
All 134 patients with PTE entered follow-up. The mean follow-up period was 25 months Ϯ 12 (range, 3-47 months). In 134 patients, the numbers of those who were followed up for fewer than 12 months, 12-23 months, 24 -35 months, and 36 -47 months were 18 (13%), 43 (32%), 37 (28%), and 36 (27%), respectively. LTP was observed in 16 (12%) of 134 patients, with occurrence in all at 2-17 months (mean, 8 months Ϯ 5) after the initial treatment. LTP rates were significantly higher in patients with an elevated serum ALT level than in those with normal values in the multivariate analysis (P ϭ .023) ( Table 3) . Seven of 16 patients with LTP were treated with multipronged ethanol ablation again. The other nine patients underwent resection (n ϭ 1), RF ablation (n ϭ 3), microwave ablation (n ϭ 3), or transarterial chemoembolization (n ϭ 2). At 2-28 months (mean, 7 months Ϯ 6) after the initial ethanol ablation, the DR rate was 34% (46 of 134), which was significantly associated with tumor type (P ϭ .001) and cirrhosis (P ϭ .01) ( Table 3) . Results with the Cox proportional hazards regression model indicated that both tumor type and cirrhosis were independent risk factors for DR. Among 46 patients with DR, 43 received additional treatments, including the following: ethanol ablation, 11 patients; RF ablation, 13; microwave ablation, 10; transarterial chemoembolization, six; and liver transplantation, three. Three patients resorted to using Chinese herbs, 
Side Effects and Complications
Fifty-two (37%) of 141 patients complained of grade 1 (Common Toxicity Criteria, version 2.0; National Cancer Institute, Bethesda, Md) pain during the procedure, and the pain was relieved immediately after completion of the ethanol injection. Fifty-one (36%) of 141 patients had a low-grade fever lasting 12-72 hours after the treatment. In most of the patients, both serum ALT and aspartate aminotransferase levels increased two to six times over the baseline levels during the first 3-5 days following the treatment. Two patients complained of grade 2 pain at the treatment site, and this pain was relieved with the use of analgesics. Asymptomatic self-limiting intraperitoneal bleeding (n ϭ 1), transient gross hematuria (n ϭ 2), and asymptomatic pleural effusion (n ϭ 3) were observed in six patients and required no medical intervention. Major complications occurred in three (2%) of 141 patients and included hepatic encephalopathy requiring emergent treatment (n ϭ 1), infarction of the left lateral liver lobe requiring antibiotics and analgesics (n ϭ 1), and liver abscess requiring drainage (n ϭ 1) ( Table 4 ). All patients with major complications recovered in 1 month. Tumor seeding was not found in any patient. There was no treatment-related death. In the univariate analysis, the diameter of the main tumor (Յ3.0 cm vs Ͼ3.0 cm, P ϭ .002), ethanol volume per tumor (Յ30 mL vs Ͼ30 mL, P ϭ .021), and ethanol volume per patient (Յ40 mL vs Ͼ40 mL, P ϭ .032) were significantly related to the occurrence of complications, but only ethanol volume per patient was an independent risk factor in the multivariate analysis.
Discussion
With conventional ethanol ablation, a complete necrosis rate of 80% is achieved in HCC smaller than 3.0 cm but only a rate of 50% in those 3.0 -5.0 cm in size (6, 7, 14) . In a randomized study (17) for treatment of HCC of 4.0 cm or smaller in size, complete tumor necrosis of 70% was achieved with conventional ethanol ablation and the use of a single 22-gauge percutaneous transhepatic cholangiographic needle, 2-5 mL of ethanol per session, and six to 12 sessions. Complete necrosis of 72% was achieved with higher-dose ethanol ablation and two to three percutaneous transhepatic cholangiographic needles, 4 -10 mL of ethanol per session, and three to six sessions (17) . The 2-year LTP rate was observed to be 33%-43% for conventional ethanol ablation (17, 27) and 24% for higherdose ethanol ablation (17) . In the current study, a PTE rate of 99% in HCCs smaller than 3.0 cm and 90% in HCCs of 3.0 -5.0 cm was achieved with multipronged ethanol ablation, with 1.1 treatment sessions and an LTP rate of 14%. Local effectiveness obtained in the present study demonstrates that, with multipronged ethanol ablation, the shortcomings of conventional ethanol ablation may be overcome by allowing a single session and 3-day hospitalization to eradicate tumors of 5.0 cm or smaller. This technique appears to offer multiple advantages. First, ethanol injected simultaneously through three prongs and in 12 directions may accomplish homogeneous alcohol distribution in the whole tumor tissue, because ethanol usually diffuses for a radius of 2-3 cm around a single needle tip toward the periphery of the tumor (28) . The IRI maneuver probably helps distribute the ethanol more evenly within the tumor. Second, the multipronged technique allows infusion of ethanol in large aliquots with one injection. A study in animals has shown that the multipronged technique enabled greater fluid infusion (mean, 15-53 mL Ϯ 3) into a solid tumor than did standard needle injection (mean, 8 mL Ϯ 1) before reflux was observed at the puncture site (24) . With the multiple-needle ethanol ablation technique, complete necrosis of target tumors could be achieved, but an average of six sessions and 10 days of hospitalization were required to complete a treatment course (18) . Third, the retractable tines that can be deployed up to 5.0 cm may ‡ This 64-year-old male patient with Child-Pugh class B disease had hepatic encephalopathy 2 days after treatment. This complication was a major one, which required hospital admission and intensive medical intervention, but the patient recovered. § This 47-year-old male patient had two tumors, both located at segment III, and injection of 60 mL of ethanol resulted in infarction of the whole left lateral lobe (segments II and III). This complication was a major one, which required hospital admission and intensive medical intervention, but the patient recovered. This 73-year-old male patient had a liver abscess after the treatment of a 4.2-cm-diameter tumor. This complication was a major one, which required hospital admission and intensive medical intervention, but the patient recovered.
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make it possible not only to completely eradicate tumors but also to provide an ablation margin to reduce possible LTP, because tumors smaller than 2.0 cm in size already manifest local micrometastases located less than 1 cm from the parent nodule (29) . In conventional ethanol ablation, ethanol is delivered into the tumor in small aliquots (2-10 mL) at multiple sessions. A high-dose single-session strategy was used in our treatment scheme. The mean dose of injected ethanol was 31 mL per tumor. The formula
] used for tumors 3.0 cm or smaller was much greater than the volume of the tumor, and a PTE rate of 99% was achieved, with a major complication rate of 0%. The ethanol injected simultaneously in multiple directions seemed to have produced thorough necrosis of the whole tumor. However, the increased risks of ethanol toxicity must be considered when ethanol is used in large aliquots, because an amount of ethanol larger than 40 mL per patient can induce a choking sensation, cough, or tachycardia, and an amount larger than 60 mL may cause respiratory depression (25) . Hence, for ablation of tumors of 3.1-5.0 cm, the amount of injected ethanol was equal to or only slightly greater than the volume of the target tumor. The results revealed that this dosage could achieve a PTE of 90%, with a 2% major complication rate in those tumors. We believe that this dosage protocol could achieve an appropriate balance between local effectiveness and the occurrence of complications.
Necrosis in capsulated tumors was more easily achieved than that in noncapsulated tumors in our study, regardless of size. Tumor pattern was the only independent risk factor of PTE. Perhaps the presence of a capsule may have prevented the ethanol from leaking outside of the tumor, thereby contributing to the complete tumor destruction.
Tumor diameter was a substantial factor of PTE in the univariate analysis. In fact, six (86%) of seven of those tumors in which treatment failed were larger than 3.0 cm. The ethanol volume chosen for treatment of larger tumors may not have been enough to infiltrate the whole tumor tissue, when considering a balance to avoid adverse effects of ethanol toxicity. A potential solution to this problem might be repeated injections or combined use of RF ablation and ethanol ablation.
The major complication rate found in this study (2%, three of 141) is similar to that of conventional ethanol ablation or RF ablation, with rates of 1.7%-2.2% (7, 19) . Of note, however, is the fact that the complication rate for treating tumors in unfavorable locations was not higher than that for treating tumors in a favorable location. These results demonstrate that multipronged ethanol ablation is safe in eradicating HCC up to 5.0 cm, no matter whether the location is favorable or unfavorable. There were three severe complications in the current study, including one case of hepatic encephalopathy that occurred in a patient with ChildPugh class B disease after injection of 46 mL of ethanol, one infarction of the left lateral lobe that occurred after injection of 60 mL of ethanol, and one liver abscess that formed after injection of 39 mL of ethanol. Therefore, the toxicity of ethanol in high-dose ethanol ablation treatment should not be underestimated.
DR was more commonly observed in patients with primary rather than recurrent HCC, which is similar to information in another report about RF ablation and microwave ablation (30) . Cirrhosis is also known to play a significant role in the occurrence of DR after curative treatments of HCC such as hepatectomy (31) , and this result, too, was found in our study.
RF ablation is now the most popular ablation modality for HCC. With RF ablation, a PTE rate of 90% and a LTP rate of 10%-14% can be achieved, with 1.1 sessions, in early-stage HCC and complete ablation of 60%-70% in 3.0 -5.0-cm tumors (17, 22) . Our data indicate that multipronged ethanol ablation has similar local effectiveness. An advantage of the multipronged technique is that 63% of tumors in the present study were located in sites that were considered unfavorable for RF ablation, and in patients who underwent treatment for such tumors, no significant differences in PTE and LTP rates were observed when these rates were compared with those for tumors in favorable locations. These results demonstrate that multipronged ethanol ablation could be used as a useful alternative to RF ablation.
The major limitation of our study was that it dealt with a single arm of HCC treatment and, therefore, lacked any direct comparison with conventional ethanol ablation or RF ablation. Randomized clinical trials with multiple treatment arms are needed to provide a complete evaluation of this newer ablation technique for the treatment of HCC.
In conclusion, high-dose single-session multipronged ethanol ablation can be used to treat early-stage or recurrent HCC up to 5.0 cm effectively and safely and may be applied even for lesions at high-risk locations. Multipronged ethanol ablation should be carefully used in patients with inadequate hepatic function or those with large tumors.
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